Effentora & Abstral

Cephalon UK and ProStrakan have both launched a new opioid formulation for the treatment of breakthrough pain in adult cancer patients already using opioid therapy.


Cephalon UK has launched Effentora (fentanyl) buccal tablets for the treatment of breakthrough pain in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Effentora is available as 100, 200, 400, 600 and 800 microgram buccal tablets in packs of four.
Once exposed to moisture, an effervescent reaction delivers the active substance. Patients should remove the tablet from the blister unit and immediately place the entire tablet in the upper portion of the buccal cavity (above an upper rear molar between the cheek and gum).

Treatment should be initiated by, and remain under the guidance of, a physician experienced in the management of opioid therapy in cancer patients. Physicians should keep in mind the potential of abuse of fentanyl.

View Effentora drug record

Further information: Cephalon UK



ProStrakan has also launched a new fentanyl formulation. Abstral (fentanyl), available as 100, 200, 300, 400, 600 and 800 microgram sublingual tablets, is indicated for the management of breakthrough pain in adults using opioid therapy for chronic cancer pain. Abstral should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain.

The tablets should be placed directly under the tongue at the deepest part. They should not be swallowed, but left to dissolve in the sublingual cavity without chewing or sucking.

View Abstral drug record

Further information: ProStrakan

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in